Literature DB >> 27297279

Livedoid vasculopathy: A review of pathogenesis and principles of management.

Biju Vasudevan1, Shekhar Neema2, Rajesh Verma3.   

Abstract

Livedoid vasculopathy is a rare cutaneous disease manifesting as recurrent ulcers on the lower extremities. The ulceration results in atrophic, porcelain white scars termed as atrophie blanche. The pathogenesis is yet to be understood with the main mechanism being hypercoagulability and inflammation playing a secondary role. The important procoagulant factors include protein C and S deficiency, factor V Leiden mutation, antithrombin III deficiency, prothrombin gene mutation and hyperhomocysteinemia. Histopathology of livedoid vasculopathy is characterized by intraluminal thrombosis, proliferation of the endothelium and segmental hyalinization of dermal vessels. The treatment is multipronged with anti-thrombotic measures such as anti-platelet drugs, systemic anticoagulants and fibrinolytic therapy taking precedence over anti-inflammatory agents. Colchicine, hydroxychloroquine, vasodilators, intravenous immunoglobulin, folic acid, immunosuppressive therapy and supportive measures are also of some benefit. A multidisciplinary approach would go a long way in the management of these patients resulting in relief from pain and physical as well as psychological scarring.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27297279     DOI: 10.4103/0378-6323.183635

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN: 0378-6323            Impact factor:   2.545


  10 in total

1.  Plasminogen activator inhibitor-1: a potential etiological role in livedoid vasculopathy.

Authors:  Yimeng Gao; Hongzhong Jin
Journal:  Int Wound J       Date:  2020-10-11       Impact factor: 3.315

2.  Atypical Mycobacterial Infection Arising Amid Corticosteroid Therapy for Livedoid Vasculopathy.

Authors:  John R Edminister; Nicole Dominiak; Lorie D Gottwald
Journal:  Case Rep Dermatol Med       Date:  2019-10-07

Review 3.  Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management.

Authors:  Asli Bilgic; Salih Ozcobanoglu; Burcin Cansu Bozca; Erkan Alpsoy
Journal:  Int J Womens Dermatol       Date:  2021-09-02

4.  Adalimumab in Treating Refractory Livedoid Vasculopathy.

Authors:  Xiao-Wen Huang; Huan-Xin Zheng; Meng-Lei Wang; Wan-Mei He; Mei-Xin Feng; Kang Zeng; Li Li
Journal:  Vaccines (Basel)       Date:  2022-04-01

Review 5.  Comparative Efficacy of Rivaroxaban and Immunoglobulin Therapy in the Treatment of Livedoid Vasculopathy: A Systematic Review.

Authors:  Shivana Ramphall; Swarnima Rijal; Vishakh Prakash; Heba Ekladios; Jiya Mulayamkuzhiyil Saju; Naishal Mandal; Nang I Kham; Rabia Shahid; Shaili S Naik; Sathish Venugopal
Journal:  Cureus       Date:  2022-08-27

6.  Botulinum toxin-A: A novel treatment for livedoid vasculopathy.

Authors:  Angela M Crotty; Bianca N Eubanks; Vienna G Katana; Kevin T Wright
Journal:  JAAD Case Rep       Date:  2022-08-27

7.  Livedoid vasculopathy - A diagnostic and therapeutic challenge.

Authors:  Maria Rosa Burg; Carolin Mitschang; Tobias Goerge; Stefan Werner Schneider
Journal:  Front Med (Lausanne)       Date:  2022-10-03

8.  Use of Low-dose Oral Warfarin in Three Cases of Livedoid Vasculopathy.

Authors:  Vikrant Saoji; Bhushan Madke
Journal:  Indian J Dermatol       Date:  2017 Sep-Oct       Impact factor: 1.494

Review 9.  Lessons from dermatology about inflammatory responses in Covid-19.

Authors:  Paulo Ricardo Criado; Carla Pagliari; Francisca Regina Oliveira Carneiro; Juarez Antonio Simões Quaresma
Journal:  Rev Med Virol       Date:  2020-07-12       Impact factor: 11.043

Review 10.  From dermatological conditions to COVID-19: Reasoning for anticoagulation, suppression of inflammation, and hyperbaric oxygen therapy.

Authors:  Paulo Ricardo Criado; Hélio Amante Miot; Thais Prota Hussein Pincelli; Alexandre Todorovic Fabro
Journal:  Dermatol Ther       Date:  2020-11-30       Impact factor: 3.858

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.